Pharmalys Ltd

31/03/2026

A new study by the highlights that remains a major threat to mothers and newborns, especially in . Up to 1 in 4 pregnancies may be affected, with first-time mothers and women living with at highest risk, underscoring the urgent need for better prevention, detection, and vaccine development.

This comprehensive analysis brings renewed attention to placental malaria (PM), a condition that continues to threaten millions of pregnant women and newborns globally. Drawing on 50 studies conducted since 2013, the review confirms that placental malaria remains highly prevalent in malaria-endemic....

30/03/2026

We are proud to announce that Pharmalys has been reappointed as a member of the Global Health EDCTP3 Stakeholder Group.

As an advisory body, the Stakeholder Group plays an important role in supporting EDCTP3’s mission to advance global health research and innovation by advising on:

- Scientific, strategic, and technological priorities of the programme
- Opportunities for collaboration and synergies with adjacent sectors
- Alignment with stakeholder needs and developments in global health
- The EDCTP Forum, engaging actively and contributing to shaping its theme and content

We are honored to continue contributing our expertise alongside other partners committed to addressing global health challenges.

Read more in the latest Global Health EDCTP3 Newsletter, which includes the official announcement of the newly appointed Stakeholder Group members. Congratulations to all those appointed!

28/03/2026

Mount Sinai researchers found that can damage via -dendriticcell3 and , raising heart attack risk. A therapy reduced heart damage while keeping antiviral defense.

Mount Sinai researchers have identified a cellular mechanism linking infections from influenza A viruses (IAVs) to cardiovascular disease, providing critical insights on how influenza can damage the heart and increase the risk of a heart attack or other major cardiovascular event.

27/03/2026

On 13 March, Pharmalys’ GCLP Team Lead, Jeanette Young, delivered an engaging presentation at TASK Headquarters in South Africa, highlighting how GCLP accreditation strengthens data integrity and supports high quality clinical research. Her session brought together onsite and online attendees for a focused discussion on the value of robust quality systems in trial‑ready laboratories.

Read more here https://www.pharmalys.com/gclp-accreditation-clinical-research-laboratories-task-presentation/

26/03/2026

A recent study from Québec shows that reducing foods and foods high in saturated fat, sodium, or added sugars significantly lowers risk, even for people taking cardio protective medications. The protective effect of a healthy is independent of medication use, meaning that nutrition and medications complement each other. Using food labels to guide choices and prioritising can enhance long-term heart health.

A prospective cohort study in adults with hypertension and or hypercholesterolemia found that lower intake of ultra processed foods or foods flagged by front of pack nutrition warnings was associated with reduced cardiovascular disease risk. These associations persisted regardless of cardioprotectiv...

25/03/2026

A new study from the shows that night-time traffic noise can alter blood and levels, increasing risk for diseases. Data from over 272,000 adults across Europe revealed that exposure above 50 decibels affects metabolic biomarkers, with stronger effects above 55 dB. The findings suggest reducing night noise through urban planning and quieter building designs could protect long-term metabolic health.

A new study has found that nighttime noise exposure is associated with changes in blood cholesterol and lipid-related metabolites in adults, which are known risk factors for cardiometabolic diseases.

23/03/2026

Scientists at the have discovered a promising new approach to combat and by boosting “good” cells in tissue. Their research shows that resident macrophages, supported by the protein , help suppress inflammation caused by excess visceral fat, which is a key driver of diabetes. In preclinical studies, increasing these cells improved insulin sensitivity in overweight mice, opening the door to potential that could prevent or reverse diabetes and complement existing treatments.

Scientists at the University of Pittsburgh School of Medicine discovered a surprising new way the body can fight insulin resistance and diabetes – by boosting a special type of "good" immune cell in fat tissue.

21/03/2026

New research indicates that may cause long-term health issues beyond the initial rash, including persistent scarring and ongoing bowel, urinary, and sexual problems up to a year later. These findings highlight the need for strong follow up care across , dermatology and psychosocial support, as well as continued efforts to prevent infection.

Study finds scarring plus bowel, urinary and sexual problems more than a year after clade II mpox infection.

20/03/2026

At Pharmalys, the commitment to Quality is reflected in our internal standards and in the active contributions of our experts to the wider Quality community. Christophe Baduel, Director of Quality Management, plays a key role in advancing industry dialogue through his long-standing involvement in BPC News. His engagement helps drive meaningful knowledge-sharing, practical discussions, and continuous improvement across organisations - reinforcing the strong Quality culture that defines Pharmalys.

Read the full article here

Discover how Pharmalys creates a true culture of Quality in clinical research through expert guidance, audits, training, and active contribution to the BPC Quality community.

18/03/2026

Brazil’s new vaccine offers single-dose protection against all four strains, making it easier to reach remote Amazon communities. With over a million doses ready and more coming, it strengthens efforts to protect vulnerable populations and could transform dengue prevention across Latin America.

A world-first single-dose vaccine against dengue virus, manufactured and approved for use in Brazil, will benefit hard-to-reach populations.

16/03/2026

A new study reveals that may be circulating silently among healthy Nigerians, with infections occurring even without obvious symptoms. Researchers from , the , and partners found evidence of low-level exposure, highlighting gaps in symptom-based surveillance and the need for expanded antibody testing.

Researchers report undetected mpox exposure in Nigeria, highlighting blind spots in symptom-based disease surveillance.

14/03/2026

A new -supported video shows how studies are proving the value of and guiding immunisation strategies in , , and .

By assessing safety, effectiveness and the added benefit of the fourth dose, these studies are strengthening prevention programmes.

A newly released video titled Proving the value of malaria vaccines: how case-control studies can guide immunisation strategies looks at the value of case control studies.